ATE555785T1 - Triazolderivate als smo-antagonisten - Google Patents

Triazolderivate als smo-antagonisten

Info

Publication number
ATE555785T1
ATE555785T1 AT08742913T AT08742913T ATE555785T1 AT E555785 T1 ATE555785 T1 AT E555785T1 AT 08742913 T AT08742913 T AT 08742913T AT 08742913 T AT08742913 T AT 08742913T AT E555785 T1 ATE555785 T1 AT E555785T1
Authority
AT
Austria
Prior art keywords
triazole derivatives
smo antagonists
smo
antagonists
triazole
Prior art date
Application number
AT08742913T
Other languages
German (de)
English (en)
Inventor
James Balkovec
Rolf Thieringer
Sherman Waddell
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE555785T1 publication Critical patent/ATE555785T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT08742913T 2007-04-18 2008-04-15 Triazolderivate als smo-antagonisten ATE555785T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92501807P 2007-04-18 2007-04-18
PCT/US2008/004862 WO2008130552A1 (en) 2007-04-18 2008-04-15 Triazole derivatives which are smo antagonists

Publications (1)

Publication Number Publication Date
ATE555785T1 true ATE555785T1 (de) 2012-05-15

Family

ID=39433852

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08742913T ATE555785T1 (de) 2007-04-18 2008-04-15 Triazolderivate als smo-antagonisten

Country Status (12)

Country Link
US (1) US7691887B2 (enExample)
EP (1) EP2136803B1 (enExample)
JP (1) JP5498936B2 (enExample)
CN (1) CN101663033B (enExample)
AR (1) AR066063A1 (enExample)
AT (1) ATE555785T1 (enExample)
AU (1) AU2008241527B2 (enExample)
CA (1) CA2683946C (enExample)
CL (1) CL2008001074A1 (enExample)
PE (1) PE20090806A1 (enExample)
TW (1) TW200901987A (enExample)
WO (1) WO2008130552A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明(cyclopamine)類似物類
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
EP3190121B1 (en) 2007-12-27 2019-02-20 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction of cyclopamine 4-en-3-one derivative
CA2710377A1 (en) * 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Therapeutic cancer treatments
GB0813740D0 (en) * 2008-07-28 2008-09-03 Angeletti P Ist Richerche Biologica Therapeutic compounds
EP2334683B1 (en) * 2008-08-29 2017-03-22 MSD Italia S.r.l. Saturated bicyclic heterocyclic derivatives as smo antagonists
WO2011017551A1 (en) 2009-08-05 2011-02-10 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
AU2010321773A1 (en) * 2009-11-20 2012-06-14 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
WO2012037217A1 (en) 2010-09-14 2012-03-22 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び/又は副作用を低減するための方法および組成物
CN104324039A (zh) * 2014-10-20 2015-02-04 付茜 一种治疗人身体表面脂肪瘤的药剂及使用方法
BR112017026103B1 (pt) 2015-06-04 2023-10-03 Sol-Gel Technologies Ltd Composições tópicas com composto inibidor de hedgehog, sistema de entrega tópica e seus usos
CN108623446A (zh) * 2017-03-24 2018-10-09 北京艾德旺科技发展有限公司 一种合成3,3-二氟环丁烷甲酸的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
DE60317631T2 (de) 2002-02-01 2008-09-25 Merck & Co., Inc. 11-beta-hydroxysteroid-dehydrogenase-1-hemmer zur behandlung von diabetes, adipositas und dyslipidämie
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
CN1795181A (zh) 2003-05-29 2006-06-28 麦克公司 用作11β-羟基类固醇脱氢酶-1抑制剂的三唑衍生物
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2006078283A2 (en) 2004-04-30 2006-07-27 Genentech, Inc. Quinoxaline inhibitors of hedgehog signalling
EP1797034B1 (en) 2004-08-06 2010-06-30 Merck Sharp & Dohme Corp. Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
BRPI0514444A (pt) 2004-08-27 2008-06-10 Infinity Pharmaceuticals Inc análogos de ciclopamina e métodos de uso destes
KR20160058972A (ko) 2004-09-02 2016-05-25 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
CN101083996A (zh) 2004-10-28 2007-12-05 Irm责任有限公司 作为hedgehog途径调节剂的化合物和组合物
CA2587489C (en) 2004-11-03 2013-12-31 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
NI200800069A (es) 2005-10-20 2008-06-25 Merck & Co Inc Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide-deshidrogenasa-1

Also Published As

Publication number Publication date
PE20090806A1 (es) 2009-06-27
CA2683946A1 (en) 2008-10-30
AR066063A1 (es) 2009-07-22
AU2008241527A1 (en) 2008-10-30
US7691887B2 (en) 2010-04-06
TW200901987A (en) 2009-01-16
CN101663033A (zh) 2010-03-03
EP2136803A1 (en) 2009-12-30
JP5498936B2 (ja) 2014-05-21
AU2008241527B2 (en) 2014-02-13
CN101663033B (zh) 2013-01-16
US20080262051A1 (en) 2008-10-23
EP2136803B1 (en) 2012-05-02
CL2008001074A1 (es) 2009-06-05
JP2010524937A (ja) 2010-07-22
CA2683946C (en) 2013-01-22
WO2008130552A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
LTC2170860I2 (lt) Benzimidazolo dariniai
ATE555785T1 (de) Triazolderivate als smo-antagonisten
ATE526325T1 (de) Substituierte benzimidazole als kinaseinhibitoren
EP2194045A4 (en) Substituted pyrazole derivative
ATE540942T1 (de) Imidazolderivate als ccr2-rezeptor-antagonisten
ATE506358T1 (de) 2-benzylpyridazinonderivate als met-kinasehemmer
ATE549340T1 (de) Spiroindolinon-derivate als mdm2-p53 inhibitoren
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
DK2351747T3 (da) Fungicide N-cycloalkylbenzylamidderivater
DK2164844T3 (da) Pyrimidinyl-pyridazinonderivater
DK2209786T3 (da) Pyrimidinsubstituerede purinderivater
BRPI0816461A2 (pt) Derivados fungicidas de 2-alquiltio-2-quinolonolóxi-acetamida
BRPI0813836A2 (pt) Derivados pirazólicos
DK2142533T3 (da) Imidazolidinonderivater
BRPI0906705A2 (pt) Composto heterocíclicos
ATE518837T1 (de) Indazolamidderivate
BRPI0915876A2 (pt) composto azol
ATE537149T1 (de) Sulfonyl-pyrazolinyl-1-carboxamidinderivate als 5-ht6-antagonisten
BRPI0817609A2 (pt) Derivados de imidazol
ATE545417T1 (de) Pyrazoloä3,4-büpyridin-derivate als phosphodiesterasehemmer
DK2152370T3 (da) Aryletherpyridazinonderivater
BRPI0810926A2 (pt) Antagonista de crig
ATE522517T1 (de) Neue imidazolderivate
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate
ATE449091T1 (de) Substituierte triazolderivate als oxytocinantagonisten